15th Conference Clinical Trials Alzheimer’s Disease, November 29- December 2, 2022, San Francisco, CA, USA: Symposia - Oral Communications - Late Breaking Abstracts (Clinical Trial Alzheimer’s Disease)

The Journal of Prevention of Alzheimer's Disease · 2022 · PMC9734311

Europe PMC

hedged sentence

0.7970

closest p · 15.9× alpha

0.7970

boldest claim

The sentences

did not reach statistical significancep=0.797not close (p > 0.1)

Mean treatment-related changes in all other AD biomarkers did not reach statistical significance (Ab40: t(4)=0.274, p=0.797, Ab1-42: t(4)=−0.092, p=0.931, p-tau 181: t(4)=−1.521, p=0.203, p-tau 181/Ab1-42: t(4)=−0.869, p=0.434, p-tau 231: t(4)=−0.152, p=0.887, NFL: t(4)=− 0.096, p=0.928).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.